Cheers to the next generation of Vanderpump Rules.” Meanwhile, Madrigal told PEOPLE on Sunday that “we shall see” if season 12, with its fresh faces, will rival the drama from seasons 1 and 2.

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease ...

Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2023 ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra showed strong Q1 2025 sales of $137.3M that highlight robust U.S. demand and early commercial momentum in non-cirrhotic NASH patients.

Madrigal Pharmaceuticals inks $2.1 billion deal with Chinese firm for MASH treatment, aiming to enhance Rezdiffra's efficacy through combination therapy.

After Shay, 40, spoke out about what led to her no longer being in contact with Vanderpump, 64, Peter Madrigal took to X on Thursday, July 24, writing, “I don’t like any old cast of VPR anymore.

Madrigal had cash, cash equivalents and marketable securities worth $848.1 million as of March 31, 2024, compared with $931.3 million as of Dec. 31, 2024.

Montgomery County pharmaceutical company Madrigal is taking its shot at succeeding where many other drug developers have previously failed in what is projected to be a multibillion-dollar market ...

Madrigal believes he “should’ve been” at the Season 10 “Vanderpump Rules” reunion as he was the “cover-up” for Leviss’ affair with Tom Sandoval.

A Madrigal Pharmaceuticals drug for the fatty liver disease NASH has data from a pivotal clinical trial showing improvements in the organ. Based on those results, which sent Madrigal's stock price ...